Workflow
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
BMYBristol-Myers Squibb(BMY) Zacks Investment Research·2024-04-09 02:31

Bristol Myers Squibb (BMY) announced that the FDA approved a label expansion for chimeric antigen receptor (CAR) T cell immunotherapy Abecma. The therapy is now approved for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.It is to be noted that Abecma is being jointly developed and commercialized in the United States by Bristol My ...